A Biorepository for Coronary Heart Disease in Qatar (QCBio)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03427489|
Recruitment Status : Completed
First Posted : February 9, 2018
Last Update Posted : August 1, 2018
Coronary heart disease (CHD) poses a major health burden in the Gulf countries. It is the leading cause of mortality and morbidity in the world and poses an enormous societal burden in the Gulf countries. Early detection of disease is imperative to reduce the health care burden and financial costs associated with CHD. Knowledge of novel genetic and proteomic markers of CHD will provide more precise estimates of risk while defining the pathways important in individual patients, revealing new targets for intervention, and ultimately enabling an individualized approach to care.
To translate recent advances in genomics and proteomics into clinical practice, these newly discovered biomarkers will need to be evaluated in patients of diverse ethnic groups with varying characteristics, environmental factors, and medication use. The investigators propose to establish a biorepository of plasma and Deoxyribonucleic acid (DNA) linked to demographic and clinical variables to facilitate biomarker studies of CHD risk, progression, and outcome. The overarching goal in developing the Qatar Cardiovascular Biorepository (QCBio) is to create a resource that fosters research aimed at identifying novel biochemical and genetic markers of CHD. A biorepository with linkage to clinical data will also provide an invaluable resource for cardiovascular research, including genomic and proteomic studies of CHD and development of biomarkers for early detection of disease and personalized drug therapy (pharmacogenetics and pharmacoproteomics).
|Condition or disease|
|Coronary Heart Disease (CHD)|
|Study Type :||Observational|
|Actual Enrollment :||2100 participants|
|Official Title:||A Biorepository for Discovering Novel Biochemical and Genetic Markers of Coronary Heart Disease in Qatar (QCBio)|
|Actual Study Start Date :||January 31, 2013|
|Actual Primary Completion Date :||March 18, 2018|
|Actual Study Completion Date :||March 18, 2018|
Coronary heart disease
Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
- Identification of genetic variants associated with CHD in Qatari Individuals using whole genome sequencing on the 2000 samples stored at the genetic biorepository over 3 years. [ Time Frame: Three years ]QCBio will create an unparalleled and unique resource for conducting genomic and studies to identify and validate biomarkers for diagnosis, prognostication, and response to therapy, in Qataris patients who have CHD or at risk
- Identification of circulating markers using plasma proteomic and metabolomic analysis in 2000 Qatari individuals with and without CHD. [ Time Frame: Three years ]Candidate approach with markers in etiologic pathways of atherosclerosis including inflammation, lipids, hemodynamic regulation, thrombosis and metabolism in addition to Agnostic approach using plasma metabolomics
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03427489
|Hamad Medical Corporation|
|Doha, Qatar, 3050|
|Principal Investigator:||Iftikhar Kullo||Mayo Clinic College of Medicine|
|Principal Investigator:||Ayman El-Menyar||Hamad Medical Corporation|
|Principal Investigator:||Jassim Al Suwaidi||Hamad Medical Corporation|